Sun Pharma slides as USFDA issues import alert on Gujarat plant

Image
Capital Market
Last Updated : Dec 08 2022 | 11:32 AM IST

Sun Pharmaceutical Industries slipped 2.61% to Rs 990.70 after the US FDA placed the Halol, Gujarat facility under import alert following the inspection conducted in May 2022.

The United States Food and Drug Administration (USFDA) conducted the inspection at its Halol, Gujarat facility from 26 April 2022 to 9 May 2022.

The import alert implies that all future shipments of products manufactured at this facility are subject to refusal of admission to the US market until the facility becomes compliant with current good manufacturing practice (cGMP) standards. The USFDA has excluded 14 products from this import alert subject to certain conditions.

The US revenues from the 14 excluded products supplied from this facility contributed to 3% of consolidated revenues in the financial year ended 31 March 2022.

The pharma company said that it continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and to ensure that the regulator is completely satisfied with the company's remedial action.

The drug maker said that it is committed to being cGMP compliant and in supplying high-quality products to its customers and patients globally.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

The pharma major's consolidated net profit rose 10.51% to Rs 2,262.22 crore on 13.11% increase in revenue from operations to Rs 10,809.19 crore in Q2 FY23 over Q2 FY22.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 08 2022 | 11:11 AM IST

Next Story